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Abstract 
Almost all T cells normally express C05, a transmembrane protein that 
regulates signaling through the T cell receptor (TCR). C05 expression on T cells 
may be tuned to the avidity of TCR interactions with their cognate peptide/ major 
histocompatibility molecule complex (MHC). In transgenic mouse model systems, 
T cells expressing receptors with high avidity for self peptides escape negative 
selection if they have high levels of C05. Conversely, peripheral T cells with low 
C05 levels selectively react with cancer cells expressing low levels of cognate 
peptide MHC complexes. In human immunodeficiency virus (HIV) infection, C05 
expression is reduced on COS+ T cells and there is evidence of abnormal COS+ T 
cell cross-reactivity. The role of C05 as a suppressor of TCR signaling suggests 
that its down-regulation in HIV infection may influence COS+ T cell cross-
reactivity. Our hypothesis is that HIV mutation generates COS+ T cell epitope 
variants with lower avidity TCR interactions and that C05 is down-regulated on 
memory T cells in adaptation. To test whether the avidity of TCR-peptide/MHC 
interaction correlates with C05 expression on cos+ T lymphocytes, T cell 
stimulation with non-HIV and HIV-derived peptides spanning 1000 fold range in 
avidity was carried out. Non-HIV infected controls were tested against 
Cytomegalovirus (CMV), Influenza (FLU), Epstein Barr virus (EBV) and self 
peptides. HIV-infected individuals were tested against the same set of peptides 
and a series of HIV peptides. COS+ T cells proliferating against different peptides 
were identified by dilution of carboxyfluorescein diacetate succinimidyl ester 
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(CFSE) fluorescence intensity and co-stained for CDS and CD5. In controls and 
HIV-infected individuals, higher proportions of CDS+ T cells against non-HIV 
peptides with high TCR-peptide/MHC interaction avidities expressed CD5. In 
general, lower proportions of CDS+ T cells against HIV-derived peptides 
expressed CD5, regardless of avidity. 
The data suggest that reduced CD5 expression is conducive to 
promiscuous activation of peptide specific cytotoxic T cells through lower avidity 
T cell receptor interactions. With reduced CD5 expression there is a lower 
threshold for activation and T cells can be activated by cross-reactive peptides 
with lower avidity for the TCR than the index peptide (primary peptide used for 
initial activation). A greater understanding of this natural immunological 
occurrence could have potential therapeutic applications. Diseases regulated by 
cell mediated immunity, including HIV infection, could potentially be treated 
through control ofT cell activation and signal modulation. The elucidation of CDS+ 
T cells lacking CD5 expression exclusively in HIV infected individuals could help 
scientists unravel new methodologies for treatment. Supported by CIHR 
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1 Introduction 
Human immunodeficiency virus (HIV-1) is a complex lentivirus (a member 
of the Retroviridae family) that causes acquired immunodeficiency syndrome 
(AIDS). This condition in humans manifests when the immune system begins to 
fail, allowing life-threatening opportunistic infections. HIV-1 primarily infects vital 
cells in the human immune system including helper T cells (specifically CD4+ T 
cells} , macrophages and dendritic cells [1 , 2]. HIV infection leads to low levels of 
CD4+ T cells through at least three mechanisms: firstly, direct viral killing of 
infected cells; secondly, increased rates of apoptosis in infected cells; and thirdly, 
killing of infected CD4+ T cells by cytotoxic CDS+ T cells that recognize infected 
cells [3, 4]. CD4+ T cells have multiple protective roles as depicted in Figure 1.1, 
and when their numbers decline below a critical protective level, cell-mediated 
immunity is compromised. 
Since HIV was first recognized on December 1, 1981 , the World Health 
Organization estimates that AIDS has killed more than 25 million people. Two 
million new deaths occurred in 2007 alone. These statistics make it the most 
destructive pandemic in recorded history [5]. Referred to as the defining public 
health crisis of our time, the Joint United Nations Program on HIV/AIDS 
(UNAIDS) as well as the World Health Organization (WHO) identify the AIDS 
pandemic as a mix of diverse epidemics from all regions of the world . Southern 
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Figure 1.1 : Simple schematic for lymphocyte activation. Green arrows represent 
cytokines and activation signals from T helper cells (T H cells). These cells 
stimulate activation of B cell proliferation and induce antibody class switching. T H 
cells augment the killing efficacy of macrophages and stimulate the expansion of 
cytotoxic CD8+ T cells through production of their associated cytokines such as 
IL-2. Persistent HIV infection leads to the loss of CD4+ helper T cells which in 
turn, decreases the availability of activation signals. The host becomes 
progressively more susceptible to opportunistic infections that are potentially 
lethal [6]. 
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Africa remains the epicenter of the pandemic and continues to have high rates of 
new HIV-1 infections [7]. The following illustration (Figure 1.2) depicts the latest 
statistics on the world pandemic of HIV and AIDS published by UNAIDSIWHO in 
July 2008, and reports to the end of 2007. 
With 2.7 million people newly infected in 2007, the total number of people 
living with HIV in 2009 is over 33 million [5]. Antiretroviral treatment reduces the 
mortality and morbidity of HIV infection, however, this treatment is not available in 
all countries. There has been no success in developing a vaccine to prevent 
infection. HIV has evolved numerous immune evasion mechanisms to allow 
entry, integration and continuous viral replication inside the host. The diversity of 
HIV together with these mechanisms and their effects over time hamper design 
and development of effective vaccines. 
1.1 HIV Summary 
1.1.1 HIV-1 structural makeup 
HIV is enveloped by a lipid bilayer of host origin in which viral 
glycoproteins are embedded as depicted in Figure 1.3. HIV is -120 nm in 
diameter and roughly spherical. HIV has several major genes coding for 
structural proteins found in all retroviruses, and several nonstructural 
("accessory") genes that are unique to HIV. Its genetic material is encoded in two 
copies of positive single-stranded RNA 97 49 bp in size, which harbor the virus' 
nine genes within a conical capsid. These genes include gag, pol, env, tat, 
1-3 
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Figure 1.2: People living with HIV infection worldwide. Modified from 
http://www. avert. org/worldstats. html 
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Figure 1.3: Illustration of HIV virion, depicting its two encapsulated copies of 
positive stranded RNA within its surrounding glycoprotein-embedded lipid 
membrane. Credit: National Institute of Allergy and Infectious Disease (NIAID) 
http://www. n ia id. nih .gov /topics/ H IVAI DS/U ndersta ndi ng/Biology /Pages/structu re.aspx 
1-5 
rev, net, vif, vpr, and vpu that collectively encode 19 proteins. Information needed 
to make the structural proteins for new virus particles is encoded by the gag, and 
env genes [8]. Gag codes for the nuclear core protein. Its precursor is 
synthesized as a 55 kDa protein which is cleaved into smaller proteins referred to 
as matrix 17 kDa (p17), capsid 24 kDa (p24), and nucleocapsid 7kDa (p7 and p6) 
[9]. The env gene codes for a glycoprotein called gp160, which is broken down to 
form transmembrane structural component proteins gp120 and gp41 [10] . They 
are found in the outer membrane of the retrovirus. Pol encodes for the Pol 
polyprotein that is broken down into protease (PR), reverse transcriptase (RT) 
and integrase (IN), all of which provide essential enzymatic functions. Similar to 
other retroviruses, the remaining six proteins encoded by HIV-1 regulatory genes 
are so-called accessory proteins; tat, rev, net, vif, vpr, and vpu, that control HIV's 
ability to infect cells, replicate, and cause disease [11]. The Tat proteins (p16 and 
p14) are transcriptional transactivators for the long terminal repeat promoter that 
act by binding the trans-activation response RNA element [1 2]. The Rev protein 
(p19) is a regulator of structural gene expression; it is involved in shuttling RNAs 
from the nucleus and the cytoplasm by binding to the Rev responsive RNA 
element [13]. The Vif protein (p23) promotes infectivity by preventing the action of 
APOBEC3G. This protein is a cytidine deaminase that induces numerous 
deoxycytidine to deoxyuridine mutations in the first negative strand of the HIV 
DNA, primarily expressed as complementary DNA. The hypermutation ultimately 
destroys the coding and replicative capacity of the virus, resulting in many non 
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viable virions [13]. The Vpr protein (p14) is a weak transcriptional activator and 
arrests cell division at G2/M [11]. The Net protein (p27) down-regulates CD4, the 
major viral receptor, and MHC class I molecules [14]. Vpu (p16) is a type I 
integral membrane protein with at least two different biological functions: it 
promotes degradation of CD4 in the endoplasmic reticulum, and it is required for 
efficient virion budding and release from the plasma membrane of HIV-1-infected 
cells [11]. 
1.1.2 Diagnosis of HIV infection 
A diagnosis of acute HIV-1 infection cannot be made with standard 
serologic tests. The recombinant enzyme-linked immunosorbent assays (ELISAs) 
commonly used to diagnose establ ished HIV-1 infection are usually negative in 
persons who present with acute infection. Serologic tests for detection of HIV-
specific antibodies first become positive approximately 22 to 27 days after acute 
infection [15]. The only test licensed for earlier detection of HIV-1 infection is the 
serum or plasma p24 antigen test, which is used routinely in blood donors to 
detect viral infection before the development of HIV-1 antibodies. Cases of acute 
HIV-1 infection have also been accurately diagnosed on the basis of high plasma 
viral RNA levels [15]. 
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1.1.3 HIV tropism 
Transmission of HIV occurs through direct contact between the 
bloodstream and/or mucosa and virions found in infected body fluids. The most 
common sources are blood, semen, and vaginal secretions [15]. HIV has been 
detected in saliva, tears, and urine, however, it is found in extremely low levels in 
these fluids [16]. 
The cells primarily infected with HIV include T H cells (CD4+ T cells) , 
dendritic cells and macrophages. The reason for this tropism is that HIV utilizes 
the CD4 molecule as the primary receptor for entry into target cells. Coreceptors 
include CCR5, exploited by R5 HIV strains and CXCR4, utilized by the X4 HIV 
strains for entry [17]. A successful infection of the targeted cell requires that HIV 
effectively transfer its genetic material into the cytoplasm. The duration and 
outcome of viral infection at the cellular level is highly dependent on the target 
cell type and its level of activation [2]. 
1.1.4 Pathogenesis 
The pathogenesis of HIV is complex and not fully understood. Infection with HIV 
follows three stages: the acute stage of infection followed by the clinical latency 
stage and lastly by AIDS. The following Figure 1.4 summarizes the course of HIV 
infection reflecting seroconversion and major changes in viremia as well the 
involvement of different cell types and changes in their numbers through to the 
development of AIDS. 
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Figure 1.4: Illustrated course of HIV-1 infection as defined by the level of 
viral replication. Plasma viremia (top graph), and dynamic changes of the CD4+ T 
cell compartments (bottom graph) occur during the course of HIV infection. 
Primary HIV infection is characterized by high plasma viremia (red line, top), low 
CD4 cells (green line, bottom), and absence of HIV-1 specific antibodies (orange 
dotted line, bottom). Seroconversion typically occurs around 4 weeks post 
exposure. Viremia falls as cytotoxic CD8+ T cells (CTL) develop (blue dotted line, 
bottom) and the individual's viral-load set point is reached during the chronic 
infection phase. The viral set points are known to differ greatly among individuals 
(red dotted line, top) and predict the rate of disease progression. Disease 
progression can range from a few years to several decades. The viral diversity 
increases throughout infection (black circles, top). The risk of HIV-1 transmission 
is highest in the first weeks of infection when viremia peaks (black circles, top). 
GALT refers to gut-associated lymphoid tissues. Figure adaptation from [2]. 
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Upon exposure to HIV, a rapid series of immunologic, virologic and clinical 
events take place. As illustrated in Figure 1.5, the primary, or acute infection, is a 
period of replication, leading to levels of HIV approaching several million viruses 
per ml in the peripheral blood [15]. The half-life of a single virion is so short that 
half of the entire plasma virus population is replaced every 30 minutes [18]. Acute 
stage infection is then followed by a characteristic drop in the number of 
circulating CD4+ T cells. Acute viremia is uniformly associated with activation of 
CDS+ T cells, as well as antibody production, or seroconversion. This stage 
usually occurs during the initial four to eight weeks post-exposure [19]. 
1.1.5 Hallmark of HIV infection 
The hallmark of HIV infection is depletion of CD4+ T cells. Bystander apoptosis 
induced by viral antigens or cytokines as well as down-regulation of CD4 receptor 
by Nef protein may be the mechanism for this sudden drop in cells. Activated 
virus-specific cytotoxic T lymphocytes (CTL) partially keep HIV infection in 
control, but eventually fail at containing the infection. HIV spread is attributed to 
its ability to effectively counteract innate, adaptive and intrinsic immunity [20]. 
HIV's ability to generate escape mutants, and establish latent provirus into the 
host genome in CD4+CD45RO+ T cells, facilitates evasion from most 
immunological attacks, including cellular and antibody-mediated immune 
responses. During the latent stage of infection, HIV actively replicates in the 
lymphoid organs. 
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Figure 1.5: HIV replication cycle depicting all major retroviral replication events 
giving rise to a mature virion. During the entry process, binding of the viral envelope 
protein (Env) to CD4 induces conformational changes in the gp120 subunit of Env, 
enabling it to interact efficiently with the chemokine co-receptors CCR5 or CXCR4. 
OThese two binding events then trigger additional irreversible conformational changes 
within the envelope external glycoprotein and transmembrane proteins that result in 
fusion of the viral and cellular membranes permitting the viral genetic material to enter 
the cell [2]. @The actual fusion event occurs within minutes of pore formation following 
release of the viral core into the cell cytoplasm [6] . Once the core disassembles, @ the 
viral genome is reverse transcribed into DNA by the viral encoded reverse transcriptase 
enzyme. Viral variants can be generated during this process since reverse transcriptase 
is error prone and has no proofreading activity [3, 21 -23]. At the midpoint of infection, 0 
the viral protein integrase in conjunction with host DNA repair enzymes inserts the HIV 
genome into transcriptionally active, gene rich regions of the host's chromosomal DNA. 
An integrase binding host factor, LEDGF/p75 (lens epithelium-derived growth factor) , 
facilitates integration, which irreversibly transforms the cell into a potential virus producer 
[2, 6]. In the late steps, 0 production of viral particles requires host as well as virus 
driven transcription. The viral proteins are 0 transported and assembled in proximity to 
the cell membrane. Virus egress from the cell is not lytic, taking advantage of the 
vesicular sorting pathway, 8 which normally mediates the budding of endosomes into 
multivesicular bodies [2] . Cleavage of the Gag-Pol polyprotein by the viral protease 
produces mature infectious virions [9]. Figure is adapted from: NIAID. 
http://www. n ia id. nih.gov /topics/H IVAI DS/Understa nd ing/Biology /Pages/hivReplicat ionCycle.aspx. 
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1.1.6 Diagnosis: AIDS 
AIDS is described as the advanced state of progressive HIV infection. In 
the absence of effective treatment, AIDS results from CD4+ T cell numbers 
profoundly decreasing over time. A person is clinically diagnosed with AIDS when 
their CD4+ T cell count falls below 200 cells per cubic millimeter of blood, the 
level at which the danger of developing an AIDS-defining illness or infection 
becomes high. In comparison, healthy individuals have about 1,000 CD4+ T cells 
per cubic millimeter of blood [2].0nce below critical numbers, cell mediated 
immunity no longer provides protection. The gradual and continuous viral 
destruction of immune cells severely compromises the host's defenses and 
allows infections that are otherwise easily dealt with . Thus these infections are 
said to be "AIDS-defining." 
1.1.7 Treatment 
There is no safe and effective vaccine against HIV despite years of 
research . Currently, antiviral drugs with harmful side effects are the only method 
of controlling HIV infection. Understanding the viral life cycle, structure and 
function of HIV proteins enabled the development of HIV-specific drugs. There 
are currently more than 20 drugs available to treat HIV-infected patients [21]. 
Introduced in 1996, Highly Active Antiretroviral Therapy (HAART) involves the 
administration of a drug combination including protease inhibitors (Pis), 
nucleoside reverse transcriptase inhibitors (RTI 's) and non-nucleoside reverse 
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transcriptase inhibitors. The implementation of HAART supports suppression of 
plasma viremia below detectable levels, raises circulating CD4+ T cell counts, 
and reduces the occurrence of opportunistic infections, thereby prolonging life 
[24]. RTis block reverse transcriptase whereas Pis prevent viral replication by 
inhibiting HIV-1 protease [25]. 
1.1.8 Persistence 
The tremendous diversity of HIV is a result of the fast viral replication 
cycle, with the generation of 109 to 1010 virions every day, coupled with a high 
mutation rate of approximately 3 x 1 o-5 per nucleotide base per cycle of 
replication [26]. This leads to the generation of many variants of HIV in a single 
infected patient. When a single cell is simultaneously infected by two or more 
different strains of HIV, such variability is compounded due to the 
recombinogenic properties of reverse transcriptase. During simultaneous 
infection, the genome of progeny virions may be composed of RNA strands from 
two different strains. These hybrid virions then infect a new cell where they 
undergo replication. As this happens, the reverse transcriptase, by jumping back 
and forth between the two different RNA templates, will generate a newly 
synthesized retroviral DNA sequence that is a recombinant between the two 
parental genomes [27]. The host cannot generate an immune response fast 
enough to keep up with the high genetic variability due to mutation and 
recombination . As cytotoxic T cell responses target dominant epitopes, the virus 
mutates and escape occurs [22]. Thus through mutation, HIV infection creates a 
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highly diverse 'quasispecies' that is a moving target [23] . The disturbing outcome 
is that the virus cannot be cleared by the host's immune system. 
1.1. 9 CD8+ T cell response 
Virus-specific cos+ T cell responses are crucial for immune control of viral 
infections and have been shown to play an important role in HIV infection [6, 2S]. 
COS+ T cells recognize viral peptides (epitopes) presented by HLA class I 
molecules on the surface of infected cells through specific binding of their T-cell 
receptor (TCR) with the HLA class 1-peptide complex. Partial control of virus 
replication is attributed to the cytotoxic T lymphocyte response where infected 
cells are destroyed by cytolytic activity [6, 29]. T cell abnormalities are a common 
occurrence in HIV infection [6]. Responding COS+ T cells in HIV infected 
individuals exhibit a modified ligand expression. There is evidence that HIV 
infection down-regulates surface MHC class I expression [30], as well as 
decreases C05 expression on COS+ T cells in HIV infected individuals [31]. Most 
abnormalities on responding HIV-specific COS+ T cells have been widely 
researched, but the effect of C05 down-regulation has never been functionally 
examined. 
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1.2 CDS 
1.2.1 Discovery 
CD5 was discovered over 30 years ago by Reinherz who produced 
monoclonal antibodies with selective reactivity against mature human thymocytes 
and peripheral human T cells [32]. CD5 was later described to be a pan T cell 
marker belonging to the cysteine-rich scavenger receptor glycoprotein family. It 
was later determined that CD5 expression increases in parallel with that of the 
CD3/TCR complex during T-cell development [33] . 
1.2.2 Structure 
CD5 contains three extracellular cysteine-rich scavenger receptor 
domains, a hydrophobic transmembrane region and a large cytoplasmic domain 
as depicted in Figure 1.6. The CD5 cytoplasmic tail is devoid of intrinsic 
enzymatic activity, but is well adapted for signal transduction. The cytoplasmic 
domain harbors four tyrosine residues at positions 378, 429, 441, and 463. 
Tyrosine 378 is contained within an immunoreceptor tyrosine-based inhibitory 
motif (ITIM). This finding suggests that CD5 interacts with intermediate proteins 
that are involved in inhibitory signaling [34]. 
In recent years, CD5 has been recognized as a modulator of TCR 
signaling [35]. It is recruited to, and tightly co-localizes with CD3 at the 
immunological synapse so as to inhibit TCR signaling in T cells interacting with 
APCs, without influencing conjugate formation [36]. COS-mediated inhibition of 
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Figure 1.6: Arrangement of CD5 extracellular region with respect to the plasma 
membrane depicting the three cysteine-rich scavenger receptor domains and 
cytoplasmic tail [37]. 
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TCR signaling does not require an extracellular domain, but only its cytoplasmic 
domain, [38] in which an ITIM motif plays an important role [34]. 
1.2.3 Biochemistry 
TCR-CD3-induced CD5 phosphorylation recruits Src-Homology 2 domain 
Phosphatase-1 (SHP-1), resulting in the activation and tyrosine 
dephosphorylation of different substrates [34]. The CD5-regulated substrates 
include CD3s, ZAP-70, Syk, and phospholipase C. The cytoplasmic domain of 
CD5 contains four potential tyrosine phosphorylation sites, including an imperfect 
immunoreceptor tyrosine-based activation motif (ITAM), and an important 
functionaiiTIM [34, 37, 39, 40]. 
By mutation of all four CD5 intracellular tyrosine residues to phenylalanine, 
the membrane-proximal tyrosine at position 378, was shown to be crucial for 
SHP-1 association [34, 37, 39]. Recruited SHP-1 associates with membrane 
receptors, regulating their function. Substrates dephosphorylated by the 
cytoplasmic tyrosine phosphatase SHP-1 include; CD3s, CD19, CD22, PIR 
B/p91A, BIT, PLCy1, and the intracellular protein tyrosine kinases p561ck, p59fyn, 
CD3<:-associated protein 70 (ZAP-70) and Spleen tyrosine kinase (Syk) [41]. The 
involvement of SHP-1 in such broad dephosphorylation affects the activation 
threshold for TCR signaling. The level of CD5 expression in combination with its 
intracellular ITIMs and recruitment of SHP-1 evidently modulates the threshold for 
activation ofT cells, [34] as illustrated in Figure 1.7. 
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Figure 1.7: The level of CD5 expression affects the activation threshold for TCR 
signaling. (A) CD5hi expressing T cells have more tyrosine phosphatase-
mediated suppression of activation by the molecule SHP-1 (Src-Homology 2 
domain Phosphatase-1) [34]. (B) CD510 T cells have a reduced threshold for 
activation due to lesser antagonistic activity. 
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1.2.4 Evidence for CDS function 
No ligand has been clearly identified for CD5 [40]. Researchers agree that 
the biological role of CD5 is to modulate the intracellular strength of signals 
induced by antigen receptors in both T cells and B cells. This is achieved by CD5 
acting as a negative regulator for TCR signaling whereby CD5 expression level 
maintains a balance between tolerance and immunity [35, 40, 42] . The molecular 
mechanisms behind the regulatory functions have only recently been elucidated. 
The critical role of CD5 ITIM has been made evident through demonstration of 
binding to SHP-1, mediating the down-regulatory activity of this receptor [34]. 
Construction of tyrosine mutants via point mutation in CD5 cytoplasmic 
ITIM removed both SHP-1 binding and the down-regulating activity of CD5 during 
TCR-CD3 stimulation [34]. These results reinforce a critical role for CD5 ITIM 
which by binding to SHP-1 mediates the down-regulatory activity of this receptor. 
Studies conducted in cell lines have revealed much about CD5 and its 
function. The regulatory role of CD5 in T cell activation was defined as inhibiting 
Ca2+ mobilization triggered via TCR-CD3 in Jurkat cells [34]. Similarly, CD8+ T 
cells that express high levels of CD5 are anergic until transferred into antigen free 
hosts where CD5 levels return to normal [43]. 
Genetic manipulation in transgenic mouse models allows control over CD5 
expression and examination of resultant T cell behavior. For instance, single 
positive thymocytes from COS-deficient mice stimulated with antibodies to CD3, 
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proliferate more efficiently than those from wild-type mice, indicating that C05 in 
immature T cells attenuates TCR-dependent signals [44]. Further support for 
C05 function was discovered when C05 expression levels on T cells were shown 
to be tuned to the avidity of TCR interactions with cognate peptide/MHC 
complexes. It was in transgenic model systems that T cells expressing receptors 
with high avidity for self peptides were shown to escape negative selection in the 
thymus if they expressed high levels of C05 [42]. Conversely, peripheral T cells 
expressing low C05 levels selectively react with cancer cells expressing low 
levels of cognate peptide MHC complexes [45]. It is very apparent that C05 
expression has modulatory effects in T cells. 
The absence of a clearly identifiable ligand is a limitation to our 
understanding of C05 biology. If a ligand were discovered , perhaps other 
functions for C05 may be identified. The knowledge of C05 function gathered to 
date suggests why we should consider C05 a homeostatic regulator of T cells. 
Therapeutic manipulation of C05 may be useful in autoimmune disease [40]. 
High levels of C05 expression would result in increased thresholds for TCR 
triggering and could be a means to control autoreactive T cells and avoid overt 
autoreactivity in the continuous presence of self antigens [43]. 
1.2.5 CD3+CD8+CD5-subset population 
In the peripheral blood there is a normal lymphoid phenotype population of 
cos- T lymphocytes mainly, C03+ COB+ [31]. In advanced stages of HIV-1 
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infection, when viral burden and replication are high, the subset population of 
C03+cos+cos- has been found to reach a mean 37.6 ± 14.S% of the total 
C03+COS+ cells [31] . This increase in cos- T cells was also evident in subjects 
with less advanced disease progression (mean 27.4 ± 13.6%). These subset 
percentage findings are significant when compared to the low mean S.S ± 3.2% 
expression of the total C03+cos+ T cells for HIV seronegative people examined 
[31]. 
1.2.6 CDS expression in HIV infection 
In HIV infection, COS expression is reduced on COS+ T cells [31] and there 
is evidence of viral-specific COS+ T cell cross-reactivity with self peptides [46]. 
The role of COS as a suppressor of TCR signaling suggests that its down-
regulation is involved in the underlying mechanism of cos+ T cell cross-reactivity 
in HIV infection. It was found that T cells lacking COS were capable of clonal 
expansion and cytolysis of autologous target cells with proportionately greater 
efficiency than the COS+ COS+ populations [47]. In 199S, lndraccolo et al. 
described a C03+cos+cos- subset population greatly expanded in the peripheral 
blood of HIV-1 infected patients. Their investigation was strictly observational and 
did not include functional experimentation. Our overall aim was to examine COS 
expression in relation to peptide-specific CTL responses of varying avidities and 
to determine if there is lower COS expression in HIV infection. 
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1.3 Study Design 
1.3.1 The importance of MHC 
The peptide/MHC complexes act as "signposts" that display fragmented 
pieces of an antigen on the host cell's surface. In humans, the MHC is divided 
into three types: Class I, II , and Ill. The A, B, and C genes belong to MHC class I. 
MHC class I is expressed on all nucleated cells. MHC class I proteins contain an 
a heavy chain and 132-microglobulin chain . They present antigen fragments to 
cytotoxic T cells and bind to CD8 on cytotoxic T cells [8]. 
In this study, the response of human histocompatibility-linked leukocyte 
antigen A2 (HLA-A2) positive individuals was chosen to be examined due to the 
high frequency of this allele in the study population. Over 50% of the HIV-
infected study cohort was previously shown to express HLA-A2. HLA-A2 is a 
good presenter of strong HIV epitopes correlating with disease progression. HIV-
uninfected volunteers were recruited , of which some had been previously fully 
typed for class I expression. As seen in Figure 1.8, flow cytometry was used to 
screen for HLA- A2 expression in new HIV-uninfected subjects. It was therefore 
desirable to screen peptides expressed in the context of HLA-A2 restriction due 
to the high frequency of HLA-A2 in the study population. The immune system of 
healthy individuals is frequently challenged with viral infections that are normally 
kept under control. Once primed, the immune system, through the generation of 
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Figure 1.8: Immunofluorescent labeling of fresh peripheral blood mononuclear 
cells (PBMC) from non-HIV infected control C32, HLA-A2 positive (a) and C34, 
HLA-A2 negative (b). HLA-A2 specific Mouse anti-Human primary monoclonal 
antibody is bound and detected by the secondary FITC conjugated goat anti-
mouse (GAM) polyclonal antibody. Blue solid peak indicates isotype control and 
the red peak indicates A2-GAM-FITC positive binding. 
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memory cells, is able to more rapidly respond against reoccurring attacks from 
these persistent viral infections. Cytomegalovirus, Influenza virus as well as 
Epstein Bar virus are among the most common viral infections that challenge the 
immune system. Through the normal generation and expansion of memory T 
cells specific to dominant epitopes of viral peptides, cell mediated immunity 
quickly assists in eliminating infected cells and with it the virus in most cases. 
lmmunodominant viral peptide-specific responses of memory CD8+ T cells were 
chosen to be examined in individuals due to their high incidence in the screened 
population. Peptides include those shown in Table 1.1. 
1.3.2 Immune response towards common viral infections 
Common viral infections that the immune system effectively eliminates or 
keeps under control include Cytomegalovirus (CMV), Epstein - Barr (EBV), and 
Influenza viruses (Flu) . Conventionally, during acute viral infection, antigen-
specific T cells expand as much as 50,000-fold, acquire effector function and 
mediate clearance of the pathogen [48]. After resolution of the infection, 90%-
95% of the antigen-specific T cells die, leaving behind a long-lived population of 
memory T cells that provide protection upon re-infection [48]. Memory T cells 
possess several properties crucial for their function, including higher frequencies 
than naive precursors, the ability to rapidly reactivate upon antigen stimulation, 
wide tissue distribution, and the ability to survive and self-renew for long periods 
in the absence of cognate antigen. Memory cells produce effector cytokines 
including IFN-y and some memory T cells have been reported to survive for as 
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Table 1.1 : HLA-A*02 restricted HIV and non-HIV peptides examined. 
HLA-A*02-
binding peptide 
A2-CMV 
A2-Fiu 
A2-IP 
A2-4 
A2-Gag 
A2-1 
A2-2 
Location 
name 
pp65 495-503 
Matrix 55-66 
BMLF1 280-288 
IP-30 -11 to -3 
PR 76-84 
P17 77-85 
RT179-187 
RT 33-41 
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Sequence 
NL1VPMV2ATV 
GILGFVFTL 
GLCTLVAML 
LLDVPTAAV 
LVGPTPVNI 
SLYNTVATL 
VIYQYMDDL 
ALVEICTEM 
Anchors 
Auxiliary anchors2 
long as 75 years [49]. This reservoir of primed cos+ T cells enables the 
investigation of peripheral viral-specific memory COS+ T cells. Examination of 
these viral specific immune responses is a method to directly study the naturally 
generated immune response established by the body that is developed 
specifically towards eliminating viral infection. 
CMV, EBV, and FLU viruses generate a variety of different host responses 
and outcomes. Flu viruses cause a self limiting disease after which the virus is 
eradicated . CMV and EBV viruses cause pauci-symptomatic or asymptomatic 
diseases after which the viruses establish lifelong latency in the host cells, but 
are kept in check by immunity. 
CMV of the Herpes virus group is found throughout all geographic 
locations and socioeconomic groups, and infects between 50% and SO% of 
adults [50]. CMV is a very potent immunogen, which triggers all arms of the 
immune system. Humoral immunity is established early in infection. However, 
the cellular immune response is considered the major mechanism by which viral 
replication is controlled. The cytotoxic cos+ T cell response is the most important 
component of CMV immune response [50, 51]. cos+ T cell responses focus on 
two CMV proteins, which are the pp65 tegument protein (protein that lines the 
space between the envelope and the nucleocapsid) and IE-1 protein (immediate-
early regulatory protein) [50]. lmmunodominant cellular responses are directed 
towards pp65 viral peptides, one of which is used in our study. 
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The Epstein - Barr virus (EBV), also from the Herpes family, is considered 
one of the most common viruses to infect humans. The majority of people 
infected with EBV remain asymptomatic but a few develop infectious 
mononucleosis. During primary infection, there is a massive expansion of 
activated antigen-specific cos+ T cells, which can persist in relatively high 
numbers for at least three years after primary infection [51]. During acute 
infection the cellular response directed towards lytic cell cycle proteins is about 
ten times stronger than the response to latent cycle proteins. EBV transactivator 
gene product BMLF1 (immediate-early promoter) is known to be an 
immunodominant antigen [52], which is used in our study. 
Each year, as many as 60 million people contract Influenza in the United 
States alone. Commonly known as the flu, this infectious disease is spread by 
RNA viruses of the family Orthomyxoviridae. The CDS+ T cell response is 
essential to clear virus. Dendritic cells and macrophages carry the antigen from 
the lungs to the lymph nodes, where they prime na·ive CDS+ T cells. The 
activated CDS+ T cells then migrate to the lungs to clear the infection. Flu-specific 
CDS+ T cells primed during primary infection persist and enable a rapid and 
vigorous response to secondary challenges [53]. Flu Matrix proteins are 
immunodominant in cellular immune responses and, therefore, are used in this 
study. 
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1.3.3 Autoreactive self peptide 
Autoreactive CDS+ T cells are selectively expanded in HIV-infected 
patients [46]. The signal peptide from an IFN-y-inducible protein, termed IP-30, is 
a dominant self peptide expressed in the context of HLA-A2. Due to its previously 
determined low avidity interaction [46] we anticipate low CD5 expression on IP-
30 peptide-specific cytotoxic T cells. 
The IP-30-specific CTL escape thymic deletion and enter peripheral 
circulation. Experimentation with IP-30 peptide ascertained failu re of the HLA-
A2:1g/IP-30 peptide dimer to stain IP-30 specific CTL. This finding suggests that 
the TCR interaction with the HLA-A2/IP-30 signal peptide complex is of relatively 
low avidity in comparison to other peptides examined [46]. 
1.3.4 The need for a therapeutic vaccine. 
Nearly three decades have passed since HIV was first identified and there 
is still much to learn about its pathogenesis. HIV infection relentlessly continues 
to spread leaving mill ions awaiting the discovery of effective treatment. 
Therapeutic vaccines hold an untapped potential in the treatment of HIV. A 
therapeutic HIV vaccine would be designed to boost the body's immune response 
to HIV in order to better control the infection. Currently, there are no therapeutic 
HIV vaccines approved by the Food and Drug Administration (FDA). However, 
therapeutic HIV vaccines are being tested in clinical trials to determine efficacy. If 
therapeutic vaccines are able to strengthen the body's natural anti-HIV immune 
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response, people with HIV will not have to rely exclusively on the antiretroviral 
drugs now used to treat HIV infection. At present, antiretroviral drugs must be 
taken for life, and most cause serious side effects. The need for alternative 
treatment arises from the multiple failed outcomes at vaccine design. The wait for 
alternative treatment is compounded by treatment regimes including HAART that 
pressure HIV to develop drug resistance through rapid turnover of viral mutants. 
These viral mutants exhibiting high fitness propel the urgency for effective 
treatment. This demand invites researchers to apply novel concepts and 
approaches to HIV research that perhaps have been overlooked. 
Greater knowledge of how the immune system responds to HIV infection 
can educate researchers towards developing effective treatment. Our study 
examines peptide-specific cos+ T cell memory responses and addresses the 
critical aspect of T cell activation with regard to varying TCR-peptide/MHC 
interaction avidity in the context of C05 expression. We explore a potential role 
for C05 in common viral infections and compare these common viral peptide-
specific COS+ T cell responses to HIV-specific COS+ T cell immune responses. 
This comparison will be made while keeping in mind that C05 attenuates TCR 
signaling [44], and its expression level positively correlates with the strength of 
TCR-induced signals [42, 54]. 
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1.4 Hypothesis 
HIV mutation generates CDS+ T cell epitope variants that have lower 
avidity TCR interactions and CD5 is down-regulated on memory T cells in 
adaptation. We therefore expect that HIV-specific T cells as well as T cells 
specific for self peptides will activate more readily upon peptide presentation 
when expression of CD5 is reduced. 
In an attempt to explore this hypothesis several research aims have been 
designed to ultimately determine if CD5 expression levels are linked to the avidity 
of the TCR-peptide/MHC interaction and to ascertain HIV's influence on CD5 
expression. 
1.5 Specific Aims 
1. Examine CDS expression on COB+ T cells from non-HIV-infected 
individuals against a set of HLA-A2 restricted immunodominant viral 
pep tides. 
2. Examine CDS expression on COB+ T cells from HIV infected individuals 
against the same set of HLA-A2 restricted non-HIV immunodominant 
viral peptides. 
3. Examine CDS expression on COB+ T cells from HIV infected individuals 
against a set of HLA-A2 restricted HIV-derived immunodominant 
peptides. 
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2 MateriaJs and Methods 
2.1 Study cohort 
Freshly isolated peripheral blood mononuclear cells (PBMC) from healthy 
uninfected and HIV-infected individuals were used in this study. Healthy 
uninfected volunteers were recruited from hospital personnel and served as the 
control group. Dr. Michael Grant's study cohort is comprised of over 240 HIV-
infected individuals recruited through the Infectious Disease Clinic of the St 
John's General Hospital, St. John's, Canada. Ethical approval for this study was 
obtained from the Memorial University Faculty of Medicine Human Investigation 
Committee and all participants provided informed consent for blood collection and 
access to clinical and laboratory records. All HIV-infected subjects have EBV-
transformed B lymphoblastoid cell lines (BLCL) generated and had been typed 
for HLA class I A and B antigens. Nearly all HIV infected subjects had been 
previously tested by cytotoxicity or ELISPOT assays for HIV-specific CDS+ T cell 
responses. 
2.2 Peptides 
We selected a variety of peptides to stimulate memory CDS+ T cell 
responses within the test subjects. Common viral peptides that are known to elicit 
CDS+ T cell responses include A2-restricted peptides from CMV, Flu, and EBV. 
These viral peptides as shown in Table 1.1 were used as controls and HIV 
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peptides including A2-4, A2-Gag, A2-1 and A2-2 served as the test peptides. Self 
peptide A2-IP was examined due to its known low TCR-peptide/MHC interaction 
avidity and ability to activate peptide-specific CDS+ T cells in HIV-infected 
individuals [46]. Synthetic peptides used were all > 95% pure (EZBiolab, Carmel, 
IN). 
2.3 Lymphocyte isolation and cell culture 
Whole blood was collected by venipuncture into Vacutainers containing 
acid-citrate-dextrose anticoagulant. Peripheral blood mononuclear cells (PBMC) 
were isolated by Ficoii-Hypaque PLUS (Amersham Biosciences AB, Uppsala, 
Sweden) gradient separation. PBMC were washed once in phosphate-buffered 
saline (PBS) and again with PBS plus 1% fetal calf serum (FCS). Cells were 
resuspended in "complete medium" consisting of RPMI 1640 supplemented with 
10% FCS, 100 IU/ml of penicillin, 100 IJg/ml of streptomycin, 2 mM L-glutamine, 
10 mM HEPES buffer solution, and 2x1 o-5 M 2-mercaptoethanol (Gibco 
Invitrogen Corporation, Grand Island, NY). For proliferation studies, AIM V 
medium was supplemented with 2 mM L-glutamine, 1% non-essential amino 
acids (Gibco Invitrogen Corporation) and 10% Human AB serum (Atlanta 
Biological, Lawrenceville, GA), 
Autologous BLCL were generated by Epstein-Barr virus transformation of 
peripheral blood B cells. In brief, 2.5 ml of supernatant from marmoset B95-8 
leukocytes (ATCC CRL 1612; Rockland, ME) was passed through a 0.45 1-1m 
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pore size sterile filter (Millipore, Bedford, MA) and added to 5 X 106 freshly 
isolated PBMC. These cells were then cultured for 24 h, washed and maintained 
in complete medium supplemented with 20% FCS and 1 1-Jg/ml of cyclosporine A 
(Sigma Aldrich, Canada) until sufficient growth occurred for cryopreservation of 
several aliquots of the cell line. 
2.4 HLA-A2 Screening 
To identify individuals expressing HLA-A2, screening was carried out using 
a HLA-A2 specific monoclonal antibody. The primary staining A2-specific-
antibody bound to the MHC and was detected with a secondary staining goat 
anti-mouse lgG fluorescein isothiocyanate (FITC) fluorochrome-conjugated 
polyclonal antibody. Positive individuals were then identified by using flow 
cytometry. Most study subjects have been fully typed for HLA class I A and B 
antigens using commercial kits (One Lambda, Canoga, CA), as previously 
described [55]. 
2.5 Identification of peptide-specific IFN-y production using 
ELISpot assay 
HLA-A2 HIV-uninfected individuals were screened for reactivity with 
peptides by ELISpot. Microtitre assay plates (Multiscreen; Millipore, Bedford, MA) 
were coated with 0.75 1-Jg/well of anti-IFN-y capture MAb, 1-D1K (Mabtech, 
Stockholm, Sweden) and left overnight at 4°C. The plates were washed six times 
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with phosphate buffered saline (PBS), and PBMC were diluted in complete 
medium to 1 x1 06/ml; 200 1-JL (2x1 05 cells) were transferred to duplicate wells 
containing 0.4 1-1M peptide of interest. Cells stimulated with 5 1-Jg/ml of purified 
phytohemagluttinin (PHA) (ICN Biomedicals Inc. , Aurora, OH) served as positive 
controls (2x1 05 cells/well). PBMC plated in absence of peptide served as a 
background control. After 16 hr incubation at 37°C in a 5% C02 incubator, plates 
were washed as above and developed as per test kit instructions. Briefly, 100 
1-JI/well of 1 1-Jg/ml biotinylated anti-IFN-y MAb 7-B6-1 (Mabtech, Stockholm, 
Sweden) diluted in PBS with 0.5% FCS was added for 2 h. Wells were washed 
six more times and 100 1-11 of streptavidin alkaline phosphatase conjugate 
(Mabtech, Stockholm, Sweden), diluted 1:1 ,000 in PBS with 0.5% FCS was 
added for 1 h. Plates were washed again six times, and 100 1-11 of chromogenic 
alkaline phosphatase substrate (Bio-Rad Laboratories, Hercules, CA) diluted 
1:100 in colour development solution was added to the wells. The plates were 
incubated with the substrate until dark spots emerged (usually between 20 min -
1 hr), at which point the wells were rinsed with tap water to terminate the color 
development reaction . The plates were then left to air dry and spots were 
counted with an automated ELISpot counter (lmmunoScan, Cellular technology 
Ltd. Cleveland, OH). Wells that produce spots were considered positive if the 
number of spots were twice the background. PHA was used as a positive control 
and PBMC alone in complete medium served as background. 
2-36 
2.6 Assessment of CDS expression on fresh PBMC 
The baseline expression of CD5 on COB+ T cells was assessed on fresh 
PBMC using triple fluorochrome staining by flow cytometry. Fluorochrome 
conjugated antibodies included CD5-allophycocyanin (APC), COB-phycoerythrin 
(PE) and CD3-FITC (All from Biolegend, San Diego, CA). The results were 
expressed as percent positive or mean fluorescence intensity of COB+ T cells that 
are CD5+. 
2.7 Assessment of CDS levels on peptide-stimulated, proliferating T 
cells. (CFSE Staining) 
1 x1 06 fresh PBMC/ml were stained with 1 IJM carboxyfluorescein 
succinimidyl ester (CFSE) (Invitrogen, Molecular Probes, Eugene, OR) diluted in 
PBS containing 5 mM ethylenediaminetetraacetic acid (EDTA) for 10 minutes at 
3rC. After staining, the cells were washed with complete medium chilled on ice. 
The cells were then pelleted and 100 IJI of test peptide at 200 IJg/ml was added to 
the appropriate tubes. Controls were PBMC incubated in the absence of peptide 
stimulation. The cells were incubated at 37°C, 5% C02 for 1 hour, then 2 ml of 
AIM V culture medium was added to the cultures and the cells were incubated for 
7 days. On day 7, the proliferating cells were identified by flow cytometry based 
on their decreased fluorescence intensity of CFSE. Cells were washed with 
fluorescence-activated cell sorting (FACS) buffer containing 5 mM EDTA, 0.5% 
bovine serum albumin, and 0.02% sodium azide (Sigma) in PBS; incubated with 
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phycoerythrin-labeled anti-human CD8 and allophycocyanin-labelled anti-human 
CD5 (All from Biolegend, San Diego, CA) at 4oC for 20 min; then washed again 
with FACS buffer and resuspended in 1% paraformaldehyde. 50,000 cellular 
events were acquired for analysis. Proliferating CD8+ T cells were gated for 
analysis and level of CD5 was examined using a FACScalibur flow cytometer. 
Peptide-specific proliferation was considered positive if the respective 
background control was below 2.5% and the proliferation was more than twice 
the background. 
2.8 Generation of Cytotoxic T cells 
Cytotoxic T cells were generated to examine functional activity. 5x1 06 
PBMC were exposed to 100 1-1M peptide in 100 1-JL of incomplete medium for 1 
hour at 37°C. The cells were resuspended at 2.5 x 1 06/mL in complete medium 
supplemented with 25 ng/mL of recombinant human interleukin 7 (IL-7) (R&D 
Systems, Minneapolis, MN) and incubated for 3 days, followed by 7-10 days 
expansion in complete medium supplemented with 10 U/mL IL-2 (Hoffmann-La 
Roche Ltd., Nutley, NJ). 
2.9 Cytotoxicity Assays 
Autologous BLCL or partially HLA-matched target cells were labeled with 
100 1-JCi Na251Cr04 (MP Biomedical , Irvine, CA) for 90 min at 3rC. Labeled cells 
were washed three times in PBS with 1% FCS, and transferred to U-bottom 96-
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well plates (Corning Inc., Corning, NY) at 5 x103 cells/well in 50 j.JI complete 
medium. To sensitize the target cells, peptides were added to the appropriate 
wells for 1 h at 3rC at a final concentration of 20 j.JM in a total of 100 j.JI complete 
medium. Sufficient effector cells were added to attain desired effector to target 
cell ratios of either 20, 10, or 5:1 and volume in each well adjusted to 300 j.JI with 
medium. The assays incubated at 3rc for 5h at which point 125 j.JI of 
supernatant was removed from each well and counted in a Wallac 1280 gamma 
counter. Spontaneous release was determined from duplicate wells containing 
51 Cr-labeled target cells in complete medium after 5 hours incubation. Maximum 
release was determined by examining duplicate wells containing 51 Cr-labeled 
target cells in 1 N hydrochloric acid after 5 hours incubation. 
Specific lysis was calculated as (experimental 51 Cr release- spontaneous 
51 Cr release) I maximum 51 Cr release - spontaneous 51 Cr release) X 100. 
Specific lysis ~ 10% above background was considered positive. 
2.10 Measurement ofTCR-peptidefMHC interaction avidities 
Effector cells from individuals with effective cytotoxic T cells generated 
against specific peptides were used to measure TCR-peptide/MHC interaction 
avidity. More specifically, autologous BLCL were pulsed with 1 0-fold dilutions of 
peptide in duplicates starting at 10 j.JM and going to 0.00001 j.JM. These BLCL 
served as targets in cytotoxicity assays. The avidity was derived from the peptide 
concentration at which specific lysis fell to 50% of maximum. 
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2.11 Statistical analysis 
Data analysis and graphical representations were performed using the 
GraphPad Prism Ver. 4.0 software package (Graph-Pad Software, San Diego, 
Ca). Statistical significance (p values) of the results was calculated by using an 
unpaired, two-tailed parametric Student's t test. A two-tailed p value of less than 
0.05 was considered significant. 
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3 Results 
3.1 Preliminary analyses 
In order to establish a solid foundation for the project, it was necessary to 
assess certain aspects of the background of our control and HIV-infected groups. 
These included: 
1) Baseline percentages of CD5+cos+ T cells in the control and the HIV-
infected population. 
2) Expression of HLA-A2. 
3) Responses by HLA-A2 subjects against common viral peptide epitopes 
from CMV, EBV, and FLU. 
3.1.1 Percentage of CDS+ T cells expressing CDS in control and HIV 
subjects. 
We tested PBMC from 17 HIV-uninfected subjects by flow cytometry to 
measure the percentage of circulating cos+ T cells expressing CD5 under 
normal conditions. Figure 3.1 summarizes the results from all 17 HIV-uninfected 
subjects. Among total CDS+ T cells in peripheral circulation, an average of 9S.2 ± 
0.3% expressed CD5. Data collected from PBMC of 32 HIV-infected subjects is 
also summarized in Figure 3.1 , which shows an average of 95.1 ± 0.4% of the 
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Figure 3.1 : Percentage of peripheral blood CD8+ T cells that express CD5 within 
our study groups. 
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total COS+ T cells in peripheral circulation express C05. Although similar, the 
fraction of COS+ T cells expressing C05 is significantly lower in the HIV infected 
group (p = 0.0001 ). In both populations, the vast majority of circulating COS+ T 
cells express C05. 
3.1.2 HLA-A2 expression in the HIV-uninfected study group 
Among the 36 subjects initially screened for HLA-A2 expression, 24 (67%) 
were found to be HLA-A2+, as reported in Table 3.1. The PBMC from these 
subjects were tested for peptide-specific IFN-y production with common A2-
restricted viral peptides using ELISpot assays. 
3.1.3 Assessment of IFN-y production following activation of 
lymphocytes by immunodominant peptides. 
Reactivity against HLA-A2-restricted, immunodominant viral peptides was 
demonstrated by IFN-y production. All 24 HLA-A2 controls were tested by 
ELISpot for reactivity against common viral peptides from CMV, FLU, EBV, and a 
self peptide A2-IP. PHA was used as a positive control and PBMC were cultured 
alone to establish background. 
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Table 3.1 : Selection of HIV-uninfected subjects expressing HLA-A2. 
HIV uninfected subject 
Cl 
C2 
C3 
C4 
cs 
C6 
C7 
ClO 
Cll 
C12 
C13 
C14 
ClS 
C16 
C17 
C18 
C19 
C20 
-~~--C21 
C22 
C23 
C24 
C25 
C26 
C27 
C28 
C29 
C30 
C31 
C32 
C33 
C34 
C35 
C36 
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HLA-A2 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Negative 
Negative 
Negative 
Positive 
Negative 
Positive 
Positive 
Negative 
Positive 
Positive 
Positive 
Positive 
Negative 
Positive 
Negative 
Negative 
Positive 
Negative 
Negative 
Positive 
Positive 
Negative 
Positive 
Negative 
~-~---. 
A representative ELISpot is shown in Figure 3.2 which illustrates within the 
screened subjects' PBMC, IFN-y release stimulated by the viral and self 
immunodominant peptides examined. Subjects C6 and C16 both demonstrated 
CMV peptide reactivity. C6 and C5 both showed EBV peptide reactivity. C6, C5 
and C16 tested positive for reactivity towards FLU peptide. Although subject C6 
appears to have produced a slight detectable response towards IP-30 peptide, 
the number IFN-y spots detected was not twice the background therefore, under 
our set criteria it was not considered a positive peptide-specific response. Subject 
C28 was shown to express HLA-A3 and not HLA-A2 by serological methods. C28 
was examined by ELISpot to confirm peptide restriction presentation by HLA-A2 
and not by HLA-A3. This subjects' PBMC served as a true negative control (data 
not shown) for identifying background. 
As summarized in Table 3.2, ELISpot testing revealed 10 (48%) subjects 
with CMV peptide reactivity, 15 (71 %) subjects with FLU peptide reactivity, 14 
(67%) subjects with EBV peptide reactivity, 2 (9.5%) subjects with IP-30 peptide 
reactivity. Three subjects (12.5%) demonstrated weak IFN-y production (close to 
background) by PHA stimulation, indicating that those PBMC samples were not 
viable. The data from those subjects with weakly stimulated PBMC were not 
included in the analysis. 
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Figure 3.2: Representative ELISpot assay, identifying PBL stimulated by 
immunodominant peptides examined in duplicate wells from 4 different HIV 
uninfected subjects C6, C5, C 16, and C28. A positive response is at least twice 
the negative control (PBL in complete medium). 
C6 
cs 
C16 
C28 
Peptide 
CMV 
Control 
subject 
IFN-y Counts 
Well1 Well2 
IFN-y/2x1 05 
PBL 
IFN-y/106 
PBL 
C6 131 137 127 635 
C5 0 0 0 0 
C16 143 151 142 710 
C28 0 0 0 0 ------------ -----------------------c6 ______________ 1"1" ___________ T3 ____________________ 5 ________________________ 2_5 _________ _ 
C5 35 16 26 130 
C16 4 3 2 10 EBV 
C28 0 0 0 0 
-----------------------------c6 ______________ j5 ____________ 29 ________________________________________ 1_2_5 _______ _ 
C5 15 11 65 
,__--:C~1~6 35 32 145 
C28 0 0 0 0 
Flu 
-------------------------c6 _________ 7 _________ f2 __________________ 3 ____________________ 1_5 __________ _ 
C5 0 1 1 5 
C16 1 3 0 0 IP 
C28 0 0 0 0 
----------------------------c6 __________ TNTC ________ TN-fc _____________ rr~.ftc ______________ l'r\ffc _______ _ 
C5 TNTC NTC TNTC TNTC 
C16 TNTC TNTC TNTC TNTC PHA 
C28 TNTC TNTC TNTC TNTC ------------------------- -------c6 ____________ 6 ________________ 7 ________________________________ tA _____ _ 
PBL C5 o o 
C16 5 4 N/A 
C28 0 0 0 N/A 
Background 
TNTC: To numerous to count 
PBL: Peripheral blood lymphocytes 
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Table 3.2: Summary of the ELl Spot results for detection of peptide-specific T cell 
IFN-y production from PBMC of 24 HIV-uninfected subjects. 
HIV uninfected Ell Spot, 
subject IFN-y response 
Cl FLU 
C2 CMV, FLU 
C3 CMV, FLU, EBV, IP 
C4 CMV, EBV 
cs FLU, EBV 
C6 CMV, FLU, EBV 
C7 EBV 
C8 EBV 
C9 CMV, FLU, EBV, IP 
ClO CMV 
Cll FLU, EBV 
C12 Weak PHA 
C16 CMV, FLU 
Weak PHA 
EBV 
C21 EBV, FLU 
C22 EBV, FLU 
C23 Weak PHA 
FLU, CMV C29 
C32 
C33 
C35 
---
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FLU, EBV 
EBV, FLU 
CMV, EBV 
3.1.4 TCR-peptidejMHC interaction avidity of immunodominant 
non-HIV peptides. 
51Cr release assays were used to determine the TCR-peptide/MHC 
interaction avidities as shown in representative Figure 3.3. Table 3.3 lists the 
non-HIV peptides examined. TCR interaction with the HLA-A2 CMV peptide 
complex is classified as high avidity. Both EBV and Flu peptides are classified as 
having intermediate binding avidity. The self peptide IP-30 HLA-A2 complex has 
the lowest TCR interaction avidity. The overall strength of the interaction 
determines the activation threshold for the responding cells activation. The 
anchor residues identified within the amino acid sequence of the peptide are 
critical for proper binding of the peptide to the HLA-A2 binding cleft. However, to 
clarify the assay, it is the overall strength (avidity) of the TCR-peptide/MHC 
interaction that is measured and not the affinity of the peptide binding to HLA-A2. 
3.1.5 Summary of preliminary analysis 
The HIV-uninfected control population, as previously shown in Figure 3.1, 
had a significantly higher basel ine CDS+ T cell CD5 expression than the HIV-
infected group. Sufficient numbers of HLA-A2 expressing subjects were identified 
within the screened population to allow for an adequate sample distribution in 
both the HIV-uninfected control and HIV-infected cohort. As previously shown in 
Table 3.2, ELISpot responses confirmed the high probability of reactivity towards 
the common viral peptides being examined. This find ing allowed selection of 
peptide-specific responders for further testing. 
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3.2 The relationship between CDS+ T cell receptor avidity and CDS 
expression for non-HIV viral peptides in HIV-uninfected subjects. 
AIM 1: Analysis of CDS expression on COB+ T cells from HIV-uninfected subjects 
reactive against HLA-A2 restricted non-HIV viral peptides. 
To test whether the avidity of TCR-peptide/MHC interaction correlates to 
C05 expression level on cos+ T lymphocytes, T cells were stimulated with non-
HIV peptides spanning a 1 000-fold range in TCR interaction avidity. HIV-
uninfected subjects were screened for reactivity towards immunodominant HLA-
A2-restricted peptides from common viruses including Cytomegalovirus, 
Influenza A, Epstein Barr and against a prominent self peptide from IFN-y-
inducible protein 30 (IP-30). The avidity of the TCR-peptide/MHC interaction was 
determined for each of the peptides examined as shown in Figure 3.3 and 
summarized in Table 3.3. Those subjects exhibiting reactivity were selected for 
further analysis of C05 expression on peptide-specific T cells using proliferation 
assays. 
Proliferation assays were performed to allow examination of cos+ T cells 
with varying C05 expression proliferating in response to the relevant peptide. In 
this way, peptide specific COS+ T cells can be identified and further characterized 
for their C05 expression by flow cytometry. Background proliferation was 
significantly reduced by using human AB serum instead of conventional FCS, 
thereby enhancing the sensitivity of this assay. 
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Figure 3.3: Specific lysis of HLA-matched, peptide-pulsed 8-lymphoblastoid cells 
(BLCL). (.) Peptide concentration eliciting 50% of maximal specific lysis was used 
as a measure of TCR- peptide/MHC interaction avidity. Dashed lines to the X axis 
indicate estimated avidity. 
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Table 3.3: TCR-peptide/MHC interaction avidity summary for non-HIV peptides. 
Peptide Amino Acid 
Sequence 
A2-CMV NL1VPMV2ATV 
A2-EBV -____;_;.G~L-':CTL VAM L 
A2-FLU GILGFVFTL 
A2-IP-30 LLDVPT AA V 
Location 
pp65 495-503 
BMLF1 280-288 
Matrix 55-66 
IP-30 -11 to -3 
Derived Avidity 
<1 ± 0.38 nM, n=16 
500 ±50 nM, n=8 
250 ±59 nM, n=13 
2000 nM* n=1 
Anchors 
2Auxiliary anchors 
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*Verified from literature [46] 
n = sample number 
Fresh PBMC were stained with CFSE. Confirmation of CFSE staining was carried 
out using a fluorescent microscope as shown in Figure 3.4. This step was 
important to assure proper staining intensity before initiation of the 7 day 
incubation with specific peptides. Responding lymphocytes undergo multiple 
divisions in culture and can thus be identified by dilution of CFSE fluorescence 
intensity. Stimulated cells were co-stained for CDS and CD5, then the CDS+ 
population was gated for analysis as shown in Figure 3.5 (A). In Figure 3.5 (B) 
The upper quadrants of the analysis contain the CD5+cos+ T cells. The lower 
quadrants depict the CD5-cos+ T cells. The right quadrants represent the 
combined CFSE high stained parental population and 100% of the non-
proliferating cells. All cells found within the left quadrants are presumed to be 
proliferating peptide-specific CDS+ T cells. The results show that 96% of the 
parental cells are CD5 positive. The upper left quadrant of the analysis 
represents the CD5 positive proliferating CDS+ T cells. The lower left quadrant 
depicts the CD5 negative proliferating CDS+ T cells. Collectively these quadrants 
depict the CFSE-Iow daughter populations and 100% of the proliferating cells. In 
this example, the high avidity TCR-peptide/MHC interactions with HLA-A2 and 
peptide from CMV produced a CDS+ proliferating T cell population (CFSE10w) that 
was 99% positive for CD5 expression. 
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Figure 3.4: Fluorescence of CFSE-stained PBMC. Freshly isolated PBMC 
stained with 1 1-1M CFSE proliferation marker and viewed under a fluorescent 
microscope at 100X magnification (Top). Unstained control PBMC viewed under 
a fluorescent microscope showing no fluorescence (lower left) . Unstained PBMC 
viewed under a light microscope (lower right) . 
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Figure 3.5: Three color flow cytometry analysis of CFSE-stained CMV peptide-
specific CDS+ T cells from subject C16. PE-Iabeled CDS+ T cells are gated for 
analysis (A). CDS+ T cells responding to A2-CMV peptide are tested for CD5 
expression using allophycocyanin-labeled anti-CD5 (CD5-APC) (B). Decreased 
fluorescence intensity of CFSE shows peptide specific CDS+ T cell proliferation 
with high CD5 expression in the upper left quadrant. 
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The results of this part of the study are summarized in Figure 3.6. The 
CMV peptide-stimulated CDS+ T cells displayed a mean CD5+ expression level of 
97.5±1.1 %, n=7. CD5 expression was consistently high on the CMV-specific CDS 
T cells in all HIV-uninfected subjects tested. The EBV peptide demonstrated a 
lower TCR avidity compared to the CMV peptide (Table 3.3). This peptide 
stimulated cos+ T cell populations with a mean 95±1 .5%, CD5+ expression n=7. 
The FLU peptide examined had a lower TCR avidity than either CMV or EBV. 
FLU peptide-stimulated cos+ T cell populations averaged 93.9±1.5% with CD5 
expression, n=10. There was no significant difference in percentage CD5 
expression between T cells responding to any of the viral peptides. Proliferation 
was also examined by stimulation with the low TCR avidity self peptide IP-30. IP-
30 has a 2000-fold lower TCR avidity compared to CMV peptide, S-fold lower 
than FLU peptide and 4-fold lower than EBV peptide. IP-30 peptide stimulated 
cos+ T cell populations with an average CD5 expression of S6.5±3.5%, n=4. This 
is significantly lower than the CDS+ T cell populations responding to CMV peptide 
(p=0.009), EBV peptide (p=0.03), or FLU peptide (p=0.05). These data suggest 
that high population levels of cos+ T cells expressing CD5 are associated with 
high avidity TCR interactions. Conversely, low avidity TCR interactions are 
associated with a lower percentage of responding T cells expressing CD5. 
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Figure 3.6: Mean percentage of peptide-specific COB+ T lymphocytes expressing 
C05 in HIV-uninfected controls. Error bars indicate standard deviation from the 
mean. T cell populations responding to non-HIV-derived viral peptides have 
significantly higher C05+ expression compared to T cells responding to the low 
TCR-peptide/MHC interaction avidity self peptide IP-30 *(p :50.05). 
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3.3 The relationship between TCR-peptide/MHC interaction avidity 
and CDS expression with non-HIV viral peptides in HIV infection. 
AIM 2: Analysis of CD5 expression on COB+ T cells from HIV individuals 
responding against HLA-A2 restricted non-HIV viral peptides. 
In order to investigate C05 expression on HIV-specific effector cells, we 
first evaluated whether HIV-infected subjects and HIV-uninfected individuals had 
similar C05 expression levels on their COS+ T cells against non-HIV peptides. If 
so, any differences observed in the COS+ T cells responding to HIV peptides 
would be specific to HIV infection and suggest selective C05 modulation on HIV-
specific COS+ T cells. C05 expression may be down regulated on expanding HIV-
specific COS+ T cells or there could be expansion of HIV-specific COS+ T cells 
clones that have a pre-existing lack of C05. Proliferation assays were conducted 
the same way for both HIV-infected and HIV-uninfected groups. HIV-infected 
individuals previously screened by ELISPOT for reactivity against non-HIV 
peptides were tested with the same set of A2-restricted immunodominant 
peptides as the non-HIV infected group. As illustrated in Figure 3.7 A, the CMV 
peptide elicited a proliferating population (CFSE10w) of 99.3% COS+ T cells 
expressing C05. Results with FLU and EBV peptides were similar to CMV 
responses. Conversely, A2-IP stimulated proliferation of a population of COS+ T 
cells with 90% C05 expression (Figure 3.7, B). This difference in the percent 
responding COS+ T cells expressing C05 between high (A2-CMV, A2-EBV, and 
A2-FLU) and low (A2-IP) TCR-peptide/MHC interaction avidity peptides was 
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Figure 3.7: Multi color flow cytometry analysis depicting CDS expression on (A) 
A2-CMV (subject 117) and (B) A2-IP reactive CD8+ T cells (subject 6S). Analysis 
of proliferating cells with decreased fluorescence intensity of CFSE show a high 
percentage of CMV-reactive CDS+ T cells expressing CDS (left quadrant) (A) and 
a comparatively lower percentage of A2-IP-reactive CDS+ T cells expressing CDS 
(left quadrant) (B). 
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seen consistently in all 36 subjects responding to peptide stimulation as 
summarized in Figure 3.S. 
CDS+ T cells responding in the context of high TCR-CMV peptide/MHC 
avidity interaction showed consistently elevated CD5 expression compared to 
other peptides examined. This observation was evident in all HIV-infected 
subjects tested. CMV peptide-stimulated CDS+ T cell populations averaged CD5 
expression on 96.5±1% of the responding CDS T cells, n=25. TCR-EBV 
peptide/MHC interaction avidity is lower than the CMV interaction. EBV peptide 
stimulated CDS+ T cell populations with 94.3±1 .7% CD5+ expression, n=16. The 
FLU peptide has a lower TCR-peptide/MHC avidity than CMV and EBV peptides, 
but stimulated proliferating populations with 94.9±1.7% CD5+ expression, n=17. 
There was no significant difference in CD5 expression observed amongst the 
responding CDS+ T cells specific for these 3 higher TCR-peptide/MHC avidity 
viral peptides. Proliferating CDS+ T cells were also examined following stimulation 
with low TCR-peptide/MHC avidity self peptide IP-30. As seen in Table 3.3, IP-30 
peptide has substantially lower TCR-peptide/MHC interaction avidity compared to 
CMV peptide (2000 fold lower), FLU peptide (S fold lower) and EBV peptide (4 
fold lower). IP-30 peptide stimulated CDS+ T cell populations which averaged a 
CD5+ expression of S5±3.4%, n=11 . Compared to all other tested non-HIV 
peptides, IP-30 reactivates the lowest percent of CDS+ T cells expressing CD5. 
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Figure 3.8: Mean percentage of proliferating CDS+ T cells expressing CDS in a 
total of 36 Hlv+ subjects responding to 1 or more non-HIV peptides. Error bars 
indicate standard deviation from the mean. CDS+ T cells, specific for self peptide 
A2-IP have significantly lower CDS expression *(p :50.0S) compared to the CDS+ 
T cells specific for non-HIV derived viral peptides. 
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The IP-30 stimulated T cells have a significantly lower CD5 expression 
than CDS+ T cells responding to CMV peptide (p=0.0005), FLU peptide (p=0.001) 
and EBV peptide (p=0.03). There was no significant difference in CD5 expression 
on non-HIV viral peptide-specific CDS+ T cells between the HIV-infected and 
uninfected group. Results in the HIV-infected group were almost identical to the 
control group. The low TCR-peptide/MHC avidity self peptide A2-IP activated 
cos+ T cells with a lower percent CD5 expression when compared to the non-
H IV peptides. 
3.4 The relationship between TCR-peptide/MHC interaction avidity 
with HIV viral peptides and CDS expression. 
AIM 3: CDS expression on COB+ T cells from HIV-infected individuals reactive 
against a set of HLA-A2 restricted HIV peptides. 
HIV-infected individuals were tested against a set of immunodominant HIV 
peptides shown in Table 3.4. This set of HIV peptides was previously determined 
to be optimal HIV-1 epitopes [56], i.e., the minimal amino acid sequence required 
forT cell stimulation has been established. As previously stated, HIV chronically 
infects the host and is never cleared by the immune system. During normal viral 
replication, the HIV genome is mutated , producing variants that consistently 
challenge the immune system to adapt to them. Aim 3 addresses my hypothesis 
that HIV mutation generates CDS+ T cell epitope variants with lower avidity TCR 
interactions and CD5 is down-regulated on memory T cells in response. This 
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reduction in CD5 expression would enable memory cos+ T cells to reactivate 
more readily to peptide stimulation. Reduced CD5 expression removes 
antagonistic dephosphorylation allowing stronger TCR-peptide/MHC interaction 
signal transduction to take place. Reduced CD5 expression could occur to 
maintain the activation potential of HIV-specific memory CDS+ T cells against 
variant peptides. The fine tuning of the CDS+ T cell activation threshold through 
altering CD5 expression potentially adapts for the changing viral peptide 
sequences created by the HIVs mutating genome. Decreased CD5 expression is 
speculated to compensate for lower TCR avidity due to the peptide amino acid 
variations generated by HIV mutation. Before examining the level of COS-
expressing cells associated with HIV peptide restimulation, the TCR-
peptide/MHC interaction avidity of each HIV peptide was determined. 
The TCR-peptide/MHC interaction avidity was measured with several HIV 
peptides as shown in Figure 3.9. Table 3.4 summarizes the findings. A2-4 had a 
very high TCR-peptide/MHC avidity interaction (<0.1 nM), followed by peptides 
A2-1 and A2-2, which both had similar TCR-peptide/MHC avidities of -10 nM. 
A2-Gag peptide demonstrated the lowest TCR-peptide/MHC interaction avidity 
amongst the HIV peptides examined of- 50 nM. 
Expression of CD5 on the HIV-specific T cells was evaluated in the HIV 
subjects using the same methodology as in the HIV uninfected subject group. 
The same screening criteria were applied to the HIV peptide-stimulated cos+ T 
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Figure 3.9: TCR-peptide/MHC interaction avidity of HIV peptides. The peptide 
concentration eliciting 50% of maximal specific lysis is taken to represent avidity 
(*). Dashed lines to the x axis indicate avidity for each peptide. 
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Table 3.4: Summary of TCR-peptide/MHC interaction avidities for HIV 
immunodominant peptides screened. 
Peptide 
A2-1 
A2-2 
A2-4 
A2-Gag 
Amino Acid 
Sequence 
VI1YQYM2DDL 
ALVEICTEM 
LVGPTPVNI 
SLYNTVATL 
Location 
RT 179-187 
RT 33-41 
PR 76-84 
P1777-85 
Derived Avidity 
10nM** n=1 
10 ± 2.5 nM, n=4 
<0.1 ± 0.18 nM, n=8 
50± 16 nM, n=6 
Anchors 
2Auxiliary anchors 
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**Verified from literature [57] 
n= Sample number 
cell proliferation data. Figure 3.10 shows the staining pattern evident for C05 
expression and CFSE intensity after HIV-specific proliferation. 
Evaluation of HIV-specific COS+ T cell proliferation demonstrates that the 
responding COS+ T cells exhibit low C05 expression similar to COS+ T cells 
proliferating in response to self peptide (IP-30). Figure 3.11 summarizes the 
variability of C05 expression on HIV-specific COS+ T cells within the 26 HIV 
infected subjects, as demonstrated in proliferation assays. Stimulation with HIV 
peptide A2-4 demonstrated that S9.4±3.6% (n=S) of the proliferating COS+ T cells 
expressed C05. The A2-4 peptide was identified to be a high TCR-peptide/MHC 
avidity interacting peptide, but, the results do not parallel with the non-HIV 
peptides responding COS+ T cells, where we observed a pattern of high C05 
expression in association with high TCR-peptide/MHC avidity. The HIV peptides 
examined, including A2-1, S6.3 ±5.7% C05 expression (n=9), may have either 
down regulated C05 or selected COS+ T cells with lower C05 expression. 
Similarly, A2-2-stimulated 84.2 ± 4.S% (n=S) C05+cos+ T cells. Both the A2-1 
and A2-2 peptides demonstrated approximately the same TCR-peptide/MHC 
interaction avidity. For HIV peptide A2-Gag, S9.9± 2.3% (n=17) of responding 
COS+ T cells expressed C05. This peptide was confirmed as having the lowest 
TCR-peptide/MHC avidity amongst the set of HIV peptides examined, as shown 
in Table 3.4. 
3-66 
A) B) 
22.8% 74.0% 14.5% 79.8% 
94% 97 83.8% 9 
...... 
' ·'"···.-. ......:--···· . I : ·.: ·= ... . :. I -~~ ... ·.:.··.. ··: · ~~ . .. .. ., -A1·;~· __ .r:r > .. 
• : • •• • • • • 0 
~ .·:' . . 
. · :. ·. 
. .·~.: _; 
,', •,/' 
.. ·= : . .. 
•:. · .. 
1.3% CFSE ·1.9% 2 .8% CFSE 
2.9% 
Figure 3.10: Multi color flow cytometry analysis depicting C05 expression on 
HIV-specific COS+ T cells from subject 105. Anti-C05 labeled with 
allophycocyanin allowed observation of C05 expression on A2-4 reactive COS+ T 
cells (A) and A2-Gag reactive COS+ T cells (B). 
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Figure 3.11: Summary of CD5 expression on HIV-specific CDS+ T cells from 26 
HIV-infected subjects. Error bars indicate standard deviation from the mean. 
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All the HIV peptides examined stimulated proliferation of CD5+ CDS+ T 
cells with a large standard deviation from the mean in terms of C05 expression. 
This distinct variance in CD5 expression level observed in responding cells was 
not evident for the control peptides examined in either the HIV-infected or 
uninfected groups and therefore, appears unique to HIV peptide-specific 
stimulation. The reduced expression of CD5 on HIV-specific T cells relative to 
CDS+ T cells specific for non-HIV viral peptides was apparent in all cases 
regardless of HIV TCR-peptide/MHC interaction avidity, (Figure 3.S and Figure 
3.11.) 
3.5 General Summary of Results 
COS+ T cells proliferating in response to different peptides were identified 
by dilution of CFSE fluorescence intensity and co-stained for CDS and CD5. In 
controls and HIV-infected individuals, a higher proportion of cos+ T cells reacting 
against high TCR-peptide/MHC interaction avidity non-HIV peptides expressed 
C05. In general, lower proportions of CDS+ T cells reactive against HIV-derived 
peptides expressed CD5, regardless of the avidity of the TCR-peptide/MHC 
interaction. Self peptide IP-30-responding COS+ T cells also demonstrated 
reduced CD5 expression in both the HIV uninfected and infected groups as 
shown in Table 3.5. C05 expression levels in the HIV group with CMV peptide 
stimulation was significantly higher (p<0.05) compared to stimulation by all HIV-
derived peptides examined: A2-1 (p=0.01), A2-2 (p=0.0005), A2-4 (p=0.01) and 
A2-Gag (p=0.005). Both A2-Fiu and A2-EBV viral peptides also induce 
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proliferation of COS+ T cells with significantly higher C05 expression (p=0.016 
and p=0.02) compared to HIV derived A2-2 peptide. It is clear from the collection 
of proliferation data as summarized in Table 3.5 that there is a significant 
distinction between the low levels of C05 expression on HIV-specific COS+ T cell 
responses, and the higher C05 expression levels on COS+ T cells responses 
against non-HIV viral peptides. HIV peptide reactivity associated with low C05 
expression may account for the cos+ T cell cross-reactivity previously observed 
[46). 
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Table 3.5: Comparative summary in HIV-infected individuals of proliferating CD8+ 
T cells expressing CD5 in response to HIV peptides and non-HIV peptides. 
A2-1 A2-2 A2-4 A2-Gag 
I CMV p=0.01 p=0.0005 p=0.01 p=0.005 
EBV NS p=0.02 NS NS 
FLU NS p=0.016 NS NS 
IP-30 NS NS NS NS 
NS: No significant difference 
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4 Discussion 
4.1 Evidence of reduced CDS expression in HIV infection. 
We studied HLA-A2 positive individuals because this allele occurs at high 
frequency (>50%) within both our HIV-uninfected and HIV infected study groups. 
Peptides were chosen based on previous demonstration of their 
immunodominance. Selected peptides exhibit optimum anchor residues for 
peptide binding to HLA-A2, preferably comprising leucine and valine at the 2nd 
and gth positions of the peptide sequence respectively [58]. We first examined 
baseline C05 expression levels on C08+ T cells in both HIV-infected and HIV-
uninfected groups. In HIV-infected subjects, fewer circulating C08+ T cells 
expressed C05 than in uninfected subjects PBMC. This is not the fi rst report of 
reduced C05 expression in HIV infection. The reported expression of C05 in our 
HIV-infected cohort corresponds to the early stages (WR1-WR3) of the Walter 
Reed HIV classification [59], as reported in lndraccolo et a/. 1995 [31]. lndraccolo 
examined C05 profiles in HIV infected subjects at all time points of disease 
progression up to and including the late stages of HIV infection (WR4-WR6) 
according to the Walter Reed staging classification , as seen in Table 4.1. Our 
collected data of C05 expression mirror lndraccolo's published reports of C05 
expression in early HIV infection [31]. lndraccolo indicated that with disease 
progression there is a significant increase in circulating Co5-C08+ T cells, as 
much as a 65% increase when comparing C05 expression from HIV-uninfected 
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Table 4.1: Walter Reed Staging Classification of HIV Infection [59] . 
Positive Chronic lymph-Antibody or CD4/mm3 DHS Thrush 
viral isolation adenopathy 
WRO >400 NL 
WR1 + >400 NL 
WR2 + + >400 NL 
WR3 + ± .<400 NL 
WR4 + ± <400 p 
WRS + ± <400 C and/or+ 
WR6 + ± <400 PC ± 
DHS = Delayed hypersensitivity 
NL =Normal 
P = Partial cutaneous anergy (cutaneous response to only one of four test antigens) 
C = Complete cutaneous anergy to four test antigens 
0.1 =Opportunistic infections 
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0.1. 
+ 
healthy controls with that of C05 expression found in late stages of HIV infection. 
Unlike lndraccolo's study, we did not analyze C05 expression according to the 
Walter Reed staging classification but, instead compared C05 expression within 
the whole HIV-infected group to C05 expression of the uninfected group. An 
important distinction would be that our HIV infected cohort are all receiving 
antiviral treatment to maintain low viral loads and thus, our cohort subjects are at 
early stages in the Walter Reid HIV staging classification. 
4.2 IFN-y produced by peptide-specific CDS+ T cells 
We identified individuals reactive with HLA-A2-restricted immunodominant 
peptides by ELISpot assays. IFN-y production is indicative of peptide-specific 
memory cos+ T cells. The majority of control individuals tested generated an 
IFN-y response to one or more of the non-HIV peptides. These individuals 
provided PBMC for peptide-specific proliferation assays using CFSE fluorescent 
staining. HIV-uninfected subjects PBMC that demonstrated peptide-specific IFN-y 
production demonstrated COS+ T cell proliferation when their PBMC were 
stimulated with the same peptide in vitro. To ensure that our examination 
included a broad spectrum of avidities the self peptide A2-IP with known low 
TCR-peptide/MHC avidity was also screened for cos+ T cell reactivity by ELl Spot 
and by CFSE proliferation assays. 
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4.3 The role of avidity in T cell activation. 
Avidity is a critical factor related to the sensitivity of initiation of cellular 
immune responses. The strength of avidity forms the culmination of T cell 
activation, influencing the delivery rate of effector cell function. The molecular 
control of avidity is complex. No single mechanism accounts for the control of 
functional avidity. The elucidation of the control of avidity would offer a substantial 
benefit. If these mechanisms were clearly identified, a number of avenues for the 
optimization of high avidity T cell activation may become apparent. In our study, 
subject PBMC that generate cytotoxic effector COS+ T cells in vitro that exhibit 
high cytolytic activity were used to measure TCR-peptide/MHC avidity. We 
describe T cell avidity as the measure of the sensitivity of a cell to peptide antigen 
stimulation. It is the strength of the overall interaction that facilitates transduction 
of the activation signal within the cell, initiated from recognition by the TCR of 
peptide bound to MHC. 
The avidities derived for all TCR-peptide/MHC interactions examined were 
reproducible with minimal variation from the mean, as shown in Table 3.3 for non-
HIV peptides and Table 3.4 for HIV peptides. Avid ities that were derived with low 
sample numbers, including A2-IP and A2-1 , were verified from previous 
publications [46] and [57]. 
4.4 CDS expression on peptide-specific T cells. 
Proliferation assays were effective in identifying COS+ T cells dividing in 
response to peptide stimulation in both the HIV-uninfected and infected groups. 
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Background proliferation was significantly reduced by substituting conventional 
FCS with human AB serum, which increased the sensitivity of this assay for 
detecting peptide specific proliferation. 
Examination of the CDS+ T cell response to non-HIV peptides showed that 
the TCR-peptide/MHC interaction avidity hierarchy correlated with CDS 
expression in non-HIV infected people. While there was no significant difference 
between CMV, EBV and FLU peptide specific responses, the peptide-specific 
cos+ T cells with high TCR avidity contain the highest percentage of CDS 
expressing cells. Conversely, low TCR-peptide/MHC interaction avidity with 
peptides (A2-IP) stimulated a lower percentage of CDS+ T cells expressing CDS. 
The same pattern was clearly observed for both HIV-infected and uninfected 
subjects. This finding agrees with the current understanding of the modulatory 
effects of CDS and avidity first proposed by Azzam et al in 199S. They suggest 
that CDS surface expression is proportional to the signaling capacity of the TCR. 
Significantly, CDS surface expression on T cells was found to directly parallel the 
avidity or signaling intensity of the positively selecting TCR-MHC-Iigand 
interaction [42]. 
The overall strength of the TCR signal transduction ultimately dictates the 
activation fate of CDS+ T cells. High avidity CTL are required for fast clearance of 
common viral infections such as CMV, FLU and EBV [60]. Our investigation 
identified high TCR-peptide interaction avidity that facilitates functional activity 
where responding T cells express higher levels of CDS. We observed that as 
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non-HIV TCR-peptide/MHC interaction avidity drops, so do the responding CDS+ 
T cells that express high levels of CD5. The self peptide A2-IP had the lowest 
TCR-peptide/MHC interaction avidity among all peptides examined and 
reactivated the highest percentage of COS+ T cells that did not express C05. We 
speculate that IP-30 self peptide-specific CDS+ T cells in the periphery that have 
low CD5 or are devoid of the CD5 receptor are rendered capable of reactivating 
in response to high amounts of self peptide which break the signaling threshold . If 
high levels of CD5 were expressed in these T cells, reactivation would most likely 
not occur. 
Our results suggest that while the host is repeatedly encountering novel 
peptide epitope variants in HIV infection, changes occur at the T cell clonal 
expansion level. During clonal expansion, selection for the alteration of CD5 
expression occurs on HIV-specific T cells compared to non HIV-specific T cells. 
We observed that the notable correlation of avidity and CD5 expression seen for 
non-HIV peptides was not evident amongst the HIV peptides examined. It 
appears that C05 expression is generally reduced in all HIV-peptide-specific T 
cells responses. Two scenarios could explain the relationship between HIV 
infection and C05 expression. At the level of the T cell population, there is either 
1) Selection for and expansion of cos+ T cells not expressing CD5 or 2) 
Modulation of C05 expression taking place within the HIV-specific CDS+ T cell 
repertoire. 
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In common viral infections such as CMV and EBV, low TCR-peptide/MHC 
interaction avidity CTL are thought to require a high peptide/MHC determinant 
density [61]. It is for this reason that CTL are unable to recognize and lyse virally 
infected target cells until later in viral development when higher amounts of 
peptide-MHC complexes are displayed at the cell surface. However, in the case 
of HIV infection, we speculate that modulation of C05 in HIV infection fine tunes 
the signal transduction sensitivity of the responding cells. This resensitization of 
the activation threshold is believed to enable HIV-specific COS+ C05- T cells to 
activate with altered peptides, which demonstrate lower TCR-peptide/MHC 
interaction avidity. 
The percentage of COS+ T cells with C05 expression in the HIV group is 
comparable to COS+ T cells responding to self peptide from both the HIV infected 
and uninfected groups. Comparatively, the HIV infected group did have a large 
variability in C05 expression on responding cos+ T cells. This may be attributed 
to different degrees of HIV progression between individuals examined . HIV 
peptides induce reactivity of a larger population of HIV-specific COS+ T cells not 
expressing C05. These findings contrast with control non-HIV peptides examined 
in the same individuals that do agree with the avidity and C05 expression 
hierarchy. Our results support evidence for the loss of C05 expression as a T cell 
adaptation and highlight how it is specific to HIV infection. 
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Nearly all peripheral blood circulating T cells are inherently C05 positive 
under normal conditions [62]. The reduced C05 expression in our study is clearly 
noticeable and expanded in HIV infected individuals. The drop in C05 expression 
according to our data is specifically attributed to HIV infection, considering that 
non-HIV viral peptides did not generate the same low C05 expression trend as 
the HIV peptides. Cellular immune responses are pressured to maintain active 
immunity in the face of a mutating HIV genome generating variant epitopes. We 
speculate that the pressure upon the host's responding T cells towards HIV 
infection creates cellular immune responses that have reset their activation 
signaling threshold . More specifically, the HIV-specific COS+ T cells have reset 
their activation potentials by reducing their C05 expression levels. COS+ T cells 
that have reduced C05 levels or none at all have a reduced threshold for 
activation due to lesser antagonistic activity from tyrosine phosphatase mediated 
suppression of activation. This resensitization is most likely accomplished 
through C05 down regulation or by selection against C05 expression on T cells 
at the clonal level, which may play several important roles in the pathogenesis of 
HIV infection. 
4.5 General Significance 
It is not clearly known whether C05 modulation is an intrinsic property of 
individual cells or if there exists a window during T cell maturation where narve 
cells maturing to effector cells modulate C05 in response to environmental 
signals, i.e., high peptide concentration, co-stimulatory molecules, or cytokines. If 
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a T cell can alter its sensitivity to peptide antigen in response to environmental 
stimuli, this would likely occur during a finite window of development. In support 
of modulation, it has been observed in previous studies that C05 levels on 
peripheral lymphocytes are susceptible to either up- or down- regulation in 
response to different experimental and/or pathological conditions. For instance, 
C05 up-regulation is also observed on peripheral T cells after TCR/C03 cross-
linking [63]. 
Alexander-Miller et al. (1996), reported that following stimulation with 
antigen presenting cells (APC) presenting a high (supraoptimal) level of peptide 
antigen, high avidity cells undergo apoptosis. Similarly, when low avidity lines are 
stimulated in the presence of low antigen, they undergo death by neglect [64]. A 
need forT cell activation modulation is a strict requirement forT cell survival and 
efficient functionality. Absence of C05 expression is not exclusively restricted to 
HIV infection. Its disruption or modulation is also found in other clinical settings. 
Hemophagocytic lymphohistiocytosis (HLH) is a severe condition characterized 
by uncontrolled activation ofT cells. EBV-associated HLH findings suggest that 
accumulation of C05- cos+ T cells may serve as a useful marker of dysregulated 
activation and proliferation [65]. Increased subpopulations of C05- COS+ T cells 
were also described in several clinical settings including allogeneic bone marrow 
transplantation [66], acute herpes virus infection [67], as well as peripheral T cell 
neoplasims [6S]. It is possible that the expansion of the C05- T cell population 
reflects a general immune dysregulation [66]. The transcription factor controlling 
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CD5 expression in CDS+ T cells remains unknown [69-71]. Ling et al (2007) 
report that GATA3 is essential for appropriate TCR up-regulation and CD5 
modulation, selectively in developing CD4+ T lineage cells. GATA3 expression is 
specifically up-regulated during development of CD4 and not CDS lineage cells 
[70], implying that the molecular mechanisms for modulation of CD5 expression 
levels during positive selection are different between the CD4 and the CDS 
lineage [71]. Although GATA3 controls the expression of CD5 during CD4+ T cell 
lineage development [71], GATA3 expression is not induced in the CDS lineage 
[69]. It appears that different nuclear factors are responsible for the regulation of 
the expression levels of CD5 in the CDS lineage [69]. 
CD5 is involved in the regulation of Fas/Fasl pathway, which is known to 
play an important role in T cell activation induced cell death (AICD). CD5 protects 
T cells from TCR activation dependent apoptosis triggered following recognition 
of the specific target. It provides survival signals to CDS+ T cells through 
regulation of Fasl expression and caspase-S activation, which supports a role for 
CD5 in the control of CDS T cell homeostasis [72]. CDS+ T cells not expressing 
CD5 may be more susceptible to apoptosis and perhaps do not last as long in the 
peripheral circulation. The T cells lacking CD5 expression that are specific for self 
peptides or HIV peptides as presented in this study may be more sensitive to 
apoptosis. This sensitivity to apoptosis may be a natural mechanism to control 
overt auto-reactivity of CDS+ T cells with self antigens. 
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The absence of C05 is believed to decrease the threshold of activation of 
HIV-specific COS+ T cells and may hold functional benefits in HIV infection. 
Within HIV infection there are escape mutants created that evade the immune 
system. We suggest that low or absent C05 expression on cos+ T cells may 
facilitate cross-reactive T cell activation and cytolysis of variant peptide-
expressing HIV-infected cells. Since C05 modulates the signaling threshold ofT 
cell activation, when C05 is reduced on T cells the threshold for activation is also 
reduced. T cells acquiring activation signals from peptide bound MHC can also 
recognize variations of peptide amino acid sequences which trigger a signal 
cascade provided the anchor residues are not disrupted. The activating T cell 
would then have a broader range of sensitivity, demonstrating promiscuous 
cytotoxicity. The data on C05 modulation in T cells, suggests such cross-
reactivity is a likely occurrence. 
4.6 Potential link between CDS expression and HIV-specific cross-
reactive CDS+ T cells. 
We speculate that low C05 expression on cytotoxic COS+ T cells allow the 
cell to interact its TCR productively with multiple peptide/MHC complexes. In the 
absence of C05, the reduced avidity interactions occur with uninhibited TCR 
signaling. The uninhibited signaling transduction may affect cytotoxic COS+ T cell 
functions by allowing cytotoxic T cells to kill a broader selection of target cells. 
The reduced C05 expression on these T cells is thought to fine tune the TCR 
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signal transduction and thus perpetuate a reduced threshold for activation of the 
cytotoxic T cell. As illustrated in Figure 4.1, the relationship between CD5 
expression and avidity of HIV specific cytotoxic T lymphocytes may reflect an in 
vivo adaptation of CDS+ T cells to HIV mutant peptides with lower TCR avidities 
than the original wild type epitope. Such occurrences would explain reported 
examples of HIV specific cross-reactivity with multiple peptides [46]. 
The strong signal generated downstream of a high avidity TCR is thought 
to induce a negative feedback in thymocytes and/or peripheral T cells, 
dampening their proliferation potential and limiting possible activation by self 
ligands. In contrast, the weak signal generated by low avidity TCR would still be 
compatible with normal survival/expansion in the periphery. Adaptation is said to 
be induced through CD5 modulation and where cells acquire improved functional 
capacities [73]. Based on the negative regulation exerted by CD5 on TCR 
signaling, it is expected that an increase in CD5 expression would decrease T 
cell reactivity and vice versa. Several observations have previously suggested 
that CD5 levels actually mirror the intensity of TCR signals [35, 54] . 
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Figure 4.1: Potential C05 expression level on HIV-Gag-specific COS+ T cells with 
cytolytic activity. Gag-specific cos+ T cells are selected from the T cell repertoire 
expressing low C05. These cells interact their TCR with A2-Gag presenting 
targets and demonstrate cross-reactivity with A2-4 presenting targets (A). Gag-
specific cos+ T cells are selected from the T cell repertoire expressing high C05. 
These cells interact their TCR with only index peptide (peptide initiating original 
activation) presenting targets. Gag-specific effectors are not cross-reactive and 
lyse only Gag presenting cells (B). Gag-specific COS+ T cells are selected from 
the T cell repertoire expressing high C05. These cells undergo modulation of 
C05 and reduce expression. These cells are then able to utilize their TCR with its 
cross-reactive potential and lyse multiple peptide presenting targets (C). 
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Initial CDS T cell 
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CDS T cell 
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5 Fumre Directions 
Future experiments should directly address the relationship between C05 
expression on HIV-specific cytotoxic T lymphocytes and their cross-reactivity with 
multiple peptides. Results from proliferation assays on peptide-specific COS+ T 
cells indicate that self peptide and HIV-specific COS+ T cells have reduced C05 
expression relative to non HIV viral peptide-specific responses. In order to 
support these findings, broadening the studies to include other HLA-class I 
molecules such as 844, 835 and A3 would be appropriate. These studies could 
generalize our evidence for a role of C05 down regulation in HIV infection. How 
C05 expression is regulated in lymphocytes and the outcome of modulation as it 
relates to cross-reactivity and tolerance requires further investigation. 
While much has been elucidated about the structure and function of C05 
[33-40, 42-45, 62, 71-S6] there is still an incomplete understanding of the function 
of C05 and how it influences the immune response. Much more research is 
required to clarify the impact of reduced C05 expression in HIV infection, and 
how modulation of C05 manipulates the immune response. Experiments that 
directly address the relationship between C05 expression on HIV-specific 
cytotoxic T lymphocytes and their cross-reactivity with multiple peptides should 
be conducted. Screening within HIV subjects and testing high and low TCR-
peptide/MHC interaction avidities with non HIV and HIV peptides could identify 
cross-reactive interactions that support our current findings. In cross-reactive 
instances, examining C05 level expression on responding cos+ T cell effectors 
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for high and low TCR-peptide/MHC interaction could clarify if low avidity 
interacting peptides generate low CD5 expressing cytotoxic effectors with cross-
reactive activity for non index peptides. Data from our lab suggest that there is 
modulation of CD5 on responding HIV peptide-specific cytotoxic T cells. 
Addressing the following unanswered questions would help clarify the role of CD5 
in the pathogenesis HIV infection. 
Do COB+ T cells with low CDS expression selectively proliferate in vivo in HIV 
infection? 
Individuals with HIV infection have challenged immune systems that are 
actively generating cytotoxic T cells against dominant HIV epitopes. We propose 
there is a relationship between reduced CD5 expression levels and proliferation 
of HIV-specific CDS+ T cells in vivo. Evaluation would involve examining co-
stained freshly isolated PBMC from HIV-infected individuals with anti-COS, anti-
CD5 and anti-Ki67 and identifying peptide-specific cos+ T cells with peptide 
bound tetramer staining. Ki-67 antigen is the prototypic cell cycle related nuclear 
protein, expressed by proliferating cells in all phases of the active cell cycle (G1 , 
S , G2 and M phase). It is absent in resting (GO) cells. Identification of peripheral 
circulating HIV-specific CDS+ T cells by tetramer staining provides an opportunity 
to assess CD5 expression while using Ki-67 antigen identification in vivo. Control 
peptides can be examined in HIV uninfected individuals. Results may distinguish 
if CD5 modulation occurs in vivo or if peptide-specific CDS+T cells with low CD5 
are selectively proliferating. 
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Do peptides demonstrating high and low TCR-peptide/MHC interaction avidity 
within subjects expressing HLA-844, 835, 857, A3 stimulate effector memory 
COB+ T cells with high and low CD5 expression? 
This examination would broaden our pool of peptide specific responders 
and potentially confirm an association between low C05 expression with 
likelihood of cross-reactivity. This finding will broaden our knowledge of C05 
modulation into other MHC restriction categories besides the currently screened 
HLA-A2 restriction. Currently in our lab, HIV peptides and self peptides restricted 
to various HLA groupings have shown peptide specific COS+ T cell activation 
from both HIV peptide and self peptide recognition . Unpublished data of CFSE 
stained PBMC demonstrate very high expansion of C05 negative peptide specific 
COS+ T cells directed towards self peptide, which merit further examination. It is 
therefore feasible to expand this aspect of the study into other HLA types. 
Do CD5 levels affect cross-reactivity spanning known cross-reactive HLA ie A2 
and A3 peptides? 
TCRs recognize antigenic peptides presented by HLA class I or class II 
molecules. The set of HLA molecules expressed in a particular person is highly 
individual and allows each person to only present a specific pattern of foreign 
peptides to the immune system. Yet, specific HLA class I alleles have a high 
degree of sequence homology and share similar peptide-binding motifs, resulting 
in the presentation of identical epitopes [S7]. The impact of this promiscuous 
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antigen presentation within one HLA on the recognition by TCRs, however, is 
currently not well understood. We propose to examine CD5 levels in cross-
reactive instances in known cross-reactive HLA. We predict that there is an 
increased likelihood that responding CD8+ T cells exhibiting cross-reactive 
tendencies across HLA may exhibit reduced CD5 expression. In this study, we 
would analyze cross-recognition of HIV-1 epitopes between major alleles, HLA-
A2 and HLA-A3 during natural HIV infection and determine to what degree the 
promiscuous presentation of a frequently targeted HIV-1 epitope by HLA-A2 and 
HLA-A3 is associated with promiscuous, cross-reactive recognition by TCRs. 
Do CDS expression levels on HIV-specific COB+ T cells support a role of CDS in 
promoting T cell survival? 
It is known that apoptosis is increased in HIV infection [4, 6, 88]. Recently 
high CD5 levels have been shown to protect T cells from TCR activation-
dependent apoptosis [72]. We predict that upon TCR activation following 
recognition of the specific target, CD5 levels may also influence apoptosis in HIV 
infected individuals. Recent research reported that CD5 prevents activation 
induced cell death in T cells through regulation of Fas/Fasl pathway as well 
CD5high T cells express lower Fasl mRNA and surface protein than CD510w T cells 
after specific stimulation [44, 83]. An examination of CD5 in our study design may 
further provide evidence for a role of CD5 in promoting T cell survival through 
modulation of Fasl expression, as a consequence of TCR-signaling inhibition. 
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6 Conclusions 
Our investigation examined CD5 expression in relation to TCR-
peptide/MHC interaction avidity for different viral specific cellular immune 
responses. It was clear that HIV peptide T cell restimulation generated a 
significantly higher proportion of CD5-CD8+ T cells in contrast to control peptides 
examined. Proliferating HIV-specific T cell CD5 levels are comparable to self 
peptide-specific CD5 expression levels. In our study this reduction in CD5 
expression was unique to HIV peptide stimulation and may relate to the high 
occurrence of cross-reactivity in HIV infection. With the confirmation that CD5 
expression is reduced in HIV specific immune responses, it would be useful to 
examine reduced CD5 expression more broadly in HIV as it relates to disease 
pathogenesis and immune response regulation. 
We believe that the examination of the effects of CD5 expression in HIV 
infection may clarify its function and influence on the immune response. CD5 
modulation has never been explored in HIV infection. Examining CD5 in a 
natural model of infection such as HIV could augment the understanding of HIV 
pathogenesis as it relates to the immune response, viral control and potential 
therapies. Inducing CD5 expression on lymphocytes may be protective in 
autoimmune diseases conversely, inhibiting CD5 expression on HIV-specific 
lymphocytes may help CDS+ T cells target multiple peptide variants of HIV 
epitopes. Clarifying the specific functional role of CD5 could support therapeutic 
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vaccine design and contribute to a better understanding of factors determining 
the nature of the CD8+ T cell immune response against HIV. 
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